T2 Biosystems Announces Kirtland Poss as Senior Vice President of Corporate Development

—Appointment Accelerates T2 Biosystems’ Expansion into Broader Market Applications of its Magnetic Biosensor Diagnostic Platforms and Products—

LEXINGTON, Mass.--(BUSINESS WIRE)-- T2 Biosystems, Inc., a company developing next-generation diagnostic products, today announced that Kirt Poss will join T2 Biosystems as Senior Vice President of Corporate Development. In this newly created position, Mr. Poss will lead T2’s market expansion strategy and related corporate partnerships, accelerating T2’s advancement in key market areas enabled by the company’s proprietary magnetic biosensor diagnostic platforms and products.

Mr. Poss joins T2Bio after completing the integration of VisEn Medical with PerkinElmer Corporation, following PerkinElmer’s acquisition of VisEn in 2010. Previously, Mr. Poss co-founded and ran VisEn as President and CEO from the company’s early technology platform formation through its product development, worldwide commercialization, and clinical partnering programs. Mr. Poss also established and led VisEn’s strategic corporate development programs, including several multi-million dollar, multi-year partnerships with leading medical system companies, pharmaceutical companies, and clinical research centers. Prior to VisEn, Mr. Poss worked in healthcare business strategy consulting for Kendall Strategies in Cambridge, MA, and prior to that worked in scientific research at the Center for Molecular Imaging Research at the Massachusetts General Hospital and Harvard Medical School. Mr. Poss holds a Bachelor of Arts degree from University of Connecticut, and is co-author on several scientific publications and multiple patents, all in the field of molecular imaging and biomarker-based clinical diagnostics.

“Kirt joins us with an exceptional background in establishing and driving long term strategy and key corporate partnerships to expand markets around fundamentally enabling technology platforms. As we continue to advance our clinical programs and see increased partnering interest in our platforms overall, Kirt’s mix of technology background and business building experience fits exceptionally well with our core strategy of both direct and partnered market expansion,” said John McDonough, President and CEO of T2 Biosystems. “Kirt’s joining is yet another key foundation for us as we continue executing on our mission of establishing the T2 technology as a new standard in the diagnostics industry.”

“With its clearly enabling magnetic biosensor platforms, deep research and development competencies, direct track into its first clinical applications and strong pipeline of addressable markets, T2 is truly advancing what is possible in the field of lab-central and decentralized diagnostics,” commented Mr. Poss. “I’m thrilled by the opportunity to join the T2 team and all of its partners in helping to both shape and drive the scope of these very exciting market opportunities.”

About T2 Biosystems, Inc.

T2 Biosystems is a private biomedical company developing next-generation medical diagnostic products using its proprietary NanoDxTM magnetic biosensor technology platforms to provide rapid, accurate and scalable diagnostics for both centralized and decentralized clinical settings. T2 Biosystems was founded in 2006 by renowned researchers from the Massachusetts Institute of Technology, Harvard University, Harvard Medical School and Massachusetts General Hospital, and has assembled a world class team, board of directors and scientific advisory board that collectively have a proven track record of translating technologic innovations into breakthrough products, building significant corporate value. T2 Biosystems is located in Lexington, Massachusetts. For more information, please visit the company's website at www.t2biosystems.com.


The Yates Network
Barbara Yates, 781-258-6153

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical